Tafasitamab and NK cells
PreclinicalCell therapy
Tafasitamab and NK cells is one of 2 small molecule programs targeting Autoimmune Disorders. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Autoimmune Disorders
#DrugCompanyPhaseTrials
1Darzalex
Johnson & JohnsonPreclinical
Tafasitamab and NK cells
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tafasitamab and NK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- MM.D. Anderson Cancer Center